Correlates of death soon after antiretroviral therapy (ART) initiation remain unclear. We investigated the association between expression of CD39, a novel immune exhaustion marker, and early mortality in patients with human immunodeficiency virus/tuberculosis co-infection. Elevated pre-ART CD39 + CD8 + T cell frequency was independently associated with mortality within 6 months of ART initiation.
T cells.
Nearly 17% of human immunodeficiency virus (HIV)-infected patients in sub-Saharan Africa die soon after antiretroviral therapy (ART) initiation [1] ; however, the immunopathogenesis of early mortality is unclear. Previously, we demonstrated that elevated baseline systemic inflammation and lack of CD4 + T cell reconstitution despite virologically suppressive ART is associated with early mortality in patients with advanced HIV/ tuberculosis (TB) co-infection [2, 3] . CD8 + T cells also mediate protective HIV-and TB-specific responses [4, 5] and may be crucial in the setting of depleted CD4 + T cells, but their relationship with mortality remains poorly defined. One mechanism linking CD8 + T cells to progressive immunosuppression and death may involve CD39. CD39 on CD4 + T-regulatory cells converts adenosine triphosphate to adenosine monophosphate, which is further processed to adenosine [6] . Adenosine binds receptors on T cells and downregulates effector responses [6] . CD39 + CD4 + T cells are implicated in inhibiting HIV-specific immune responses [7] . Whether CD39 on CD8 and early mortality utilizing a previously described cohort of patients with advanced HIV/TB co-infection initiating ART [2, 3] .
METHODS AND MATERIALS

Ethics
The University of Pennsylvania, Botswana Ministry of Health, and Princess Marina Hospital (Gaborone, Botswana) institutional review boards approved the study.
Study Design
In this secondary analysis of a prospective cohort study set in Gaborone, Botswana [2, 3] , we aimed to elucidate the association between pre-ART CD39 + CD8 + T cell frequency and mortality within 24 weeks post-ART initiation [2, 3] . We also explored the correlation between pre-ART CD39 + CD8 + T cells and cellular activation and function.
Study Participants
The parent study enrolled HIV-infected adults with pre-ART CD4 counts ≤125 cells/μL and active TB [2, 3] . Here, patients required baseline peripheral blood mononuclear cells (PBMCs) to determine CD39 expression.
Data Collection
The parent study collected pre-ART CD4 counts and HIV viral load (VL) [2, 3] . PBMCs were isolated before ART initiation [2, 3] . Patients were followed monthly for 6 months post-ART initiation [2, 3] . We retrieved clinical and flow cytometric data from the parent study database [2, 3, 10] .
Flow Cytometry
Cryopreserved PBMCs were thawed and stained with anti-CD3-BV570 (Biolegend), anti-CD8-QD605, anti-CD4-QD655 (Life Technologies), and anti-CD39-PE antibody (Biolegend).
PD-1, CD38, and HLA-DR staining is described elsewhere [10] . Pathogen-specific responses were measured by 6-hour stimulations with (1) 
Statistical Analysis
In unadjusted analyses, survivors were compared to deaths using 2-sided Wilcoxon rank-sum and χ 2 tests. In adjusted analyses of the association between CD39 + CD8 + T cells and mortality, clinical factors associated with death at P < .2 were considered potential confounders. We also determined if this association was independent of cellular activation. Due to the small sample size, each variable was tested one at a time in a base model that consisted of CD39 + CD8 + T cell frequency. Factors that changed the unadjusted odds ratio (OR) by >10% were retained in the final logistic regression model. Correlations were determined using Spearman correlation coefficient (rho, r). Stata software version 11.2 (StataCorp) was used for analyses.
RESULTS
Clinical Characteristics
Of the 170 patients who initiated ART in the parent cohort [2] , 105 (62%) had PBMCs at baseline to determine CD39 expression. Overall, patients had a median pre-ART CD4 count of 64 cells/μL (IQR, 29-95 cells/μL) and an HIV VL 5.4 log 10 copies/ mL (IQR, 5.0-5.9 log 10 copies/mL), respectively (Supplementary Table 1 ). Baseline characteristics of those included in this study were compared to 65 (38%) patients who were part of the parent study but not included here [2] (Supplementary Table 1 ). Patients in this study had slightly lower baseline HIV VL (P = .06) and were more likely to be female (P = .05) vs those not included.
CD39 + CD8 + T Cells and Early Mortality
Of the 105 patients with pre-ART CD39 data, 96 (91%) survived and 9 (9%) died within 6 months of starting ART. Significantly lower pre-ART CD4 counts (P = .02) and slightly higher HIV VL (P = .06) characterized deaths vs survivors (Table 1) . Patients who died had significantly elevated CD39 + CD8 + T cell Figures 6 and 7 ).
DISCUSSION
The current study extends our previous findings linking higher pre-ART immune activation with death in advanced HIV/TB [2, 3] , and associates CD39 + CD8 + T cells with clinical deterioration despite ART initiation. Our observations are broadly consistent with studies implicating CD39 + CD4 + T-regulatory cells with progressive HIV disease [7, 11] . Tuberculosis is a major cause of death among HIV-infected patients [13] . CD4 + and CD8 + T cells can mount anti-TB responses [5] . Furthermore, CD8 + T cells have been suggested to control TB by preferentially recognizing and eliminating cells with high bacterial load [14] . Thus, a potential mechanism for demise is suppression of these TB-specific responses that involves CD39. In one study, CD39 + CD8 + T cells downregulated TB-specific CD4 + T cell proliferation in 6-day cultures [8] . Although we found no correlation between CD39 + CD8 + T cell frequency and TB-specific CD4 + or CD8 + T cells, we could have missed an association due to our experimental design. Specifically, we used a short 6-hour stimulation; quantitated TB-specific T cell frequency rather than their proliferation; and did not assess CD39 expression on pathogen-specific T cells. While we cannot attribute causality between CD39 + CD8 + T cells and TB-associated mortality, some of our advanced HIV/ TB patients had non-TB opportunistic infections (eg, pneumocystis pneumonia, herpes zoster, and esophageal candidiasis) at the time of death [2, 3] . It is plausible that additional undiagnosed life-threatening viral infections (eg, Kaposi sarcoma-associated herpesvirus) that are typically controlled by CD8 + T cells also contributed to death. Importantly, the study demonstrating CD39 as an exhaustion marker in HIV and hepatitis C virus-infected individuals also determined that CD8 + T cells expressing high levels of CD39 had the worst virus-specific effector function using a mouse model of chronic viral infection [9] . A major limitation of our study was the small number of deaths analyzed. Additionally, some patients did not have cells available for analysis, and confirmation of these findings in an unselected cohort should be pursued. Finally, limited numbers of cells precluded us from conducting mechanistic assays to elucidate CD39 + CD8 + T cell function.
In conclusion, the association between elevated pre-ART CD39 + CD8 + T cell frequency and increased risk of death urges evaluation of these cells in greater detail. Immunotherapies blocking CD39 [15] can de-repress cancer-specific [16] and HIV-specific immune responses [7] , and could be beneficial if CD39 + CD8 + T cells contribute directly to immunosuppression in HIV/TB.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes
Financial support. This study was supported by the National Institutes of Health (grant number R01AI080337); the Penn Center for AIDS Research (grant number AI045008); and the National Center for Advancing Translational Sciences of the National Institutes of Health (grant number KL2TR001879).
Potential conflicts of interest. All authors: No reported conflicts.
